Update on Current Issues and Clinical Challenges in the Treatment of Bleeding Disorders

Click the “Start Program” button to indicate you have reviewed the CME/CE information for this activity.
Start Program


Release Date: November 8, 2017
Expiration Date: November 8, 2018
Estimated Time to Complete Activity:
Minimum System Requirements:
  • Internet Explorer 10 (or higher)
  • Mozilla Firefox 48 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 15.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Postgraduate Institute for Medicine (PIM)

Target Audience
This activity has been designed to meet the educational needs of hematologists, physicians, physician assistants, nurse practitioners, advanced practice registered nurses, registered nurses, and other specialists of the hemophilia treatment center (HTC) team, as well as other healthcare providers interested in the comprehensive care of patients with congenital or acquired hemophilia

Statement of Need/Program Overview
Hemophilia is the most common severe inherited bleeding disorder recognized in humans, and it comprises the largest proportion of patients followed in most bleeding disorder clinics and HTCs. Many of the clinicians who practice at HTCs or other types of hemophilia practices are not able to regularly attend the major national and international society meetings. They thus miss opportunities to keep abreast of the latest medical developments and to interact with experts who provide perspective and insight on a range of clinical challenges and patient management issues frequently encountered in the HTC setting. With the CME/CE NetWorkShops™ series, however, these meetings can be brought to busy clinicians in the form of webcasts and organized group workshops at or near HTCs. Healthcare professionals are now able to view, analyze, and discuss key meeting findings with recognized hemophilia experts while gaining ideas on how to apply new learnings to their own clinical practice.

Educational Objectives
After participating in this activity, participants should be able to:

  • Review clinical data about the comprehensive care of patients with hemophilia (PWH)
  • Develop novel tools and outcome measures to improve PWH/provider communication, treatment planning, and education
  • Review developments in hemophilia treatment, including newer factor concentrates, prophylactic strategies, and gene therapy
  • Assess the efficacy of novel therapeutic strategies when treating PWH with target joints
  • Implement individualized hemophilia management strategies that optimize adherence and outcomes

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation
This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Accreditation Statement

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


Instruction to Receive Credit

During the period of November 8, 2017, through November 8, 2018, participants must:

  • Read the learning objectives and faculty disclosures
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question
  • Complete the evaluation form

A statement of credit will be issued automatically upon successfully completing the post-activity survey with a score of 75% or better and submitting the activity evaluation.


Fee Information & Refund/Cancelation Policy 

There is no fee for this educational activity.

 

Planning Committee and Presenting Faculty

Chairperson
Steven W. Pipe, MD
Professor of Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, Michigan


Faculty
Miguel A. Escobar, MD

Department of Pediatrics and Internal Medicine
Division of Hematology
University of Texas and MD Anderson Cancer Center
McGovern Medical School
Medical Director, Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Amy D. Shapiro, MD
Adjunct Professor, Pediatrics
Michigan State University
East Lansing, Michigan
Medical Director & Pediatric Hematologist
Indiana Hemophilia & Thrombosis Center
Indianapolis, Indiana

Robert Sidonio Jr, MD
Associate Director Hemostasis and Thrombosis
Comprehensive Bleeding Disorder Center at
Emory University and Children’s Healthcare of Atlanta
Atlanta, Georgia

Doris Quon, MD, PhD
Medical Director
Orthopaedic Hemophilia Treatment Center
Orthopaedic Institute for Children
Los Angeles, California

Michelle L. Witkop DNP, FNP-BC
Doctor of Nursing Practice
Head of Research
National Hemophilia Foundation
New York City, New York
Bleeding Disorders Nurse Practitioner
Northern Regional Bleeding Disorders Center at Munson Medical Center
Traverse City, Michigan

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty Presenter/Planning Committee Reported Financial Relationship
Miguel Escobar, MD

Consulting Fees: Bayer, CSL Behring, Genentech, HEMA Biologics, Novo Nordisk, Shire
Contracted Research: Bayer, Biogen Idec, CSL Behring, Genentech, Novo Nordisk, Octapharma, OPKO Biologics, Pfizer, Shire

Steven W. Pipe, MD

Consulting Fees: Alnylam, Biogen Idec, CSL Behring, HEMA Biologics, Novo Nordisk, Pfizer, Roche/Genentech, Shire, uniQure. Contracted Research: Siemens, Shire

Doris Quon, MD, PhD

Consulting Fees: Baxalta/Shire, Bayer, Biogen Idec, Grifols, Novo Nordisk, Pfizer
Fees for Non-CME/CE Services: Baxalta/Shire, Biogen Idec, Grifols, Novo Nordisk

Amy D. Shapiro, MD

Consulting Fees: Baxalta/Shire, Bayer, Biogen Idec, Bio Products Laboratory, Genentech, Kedrion, Prometic Life Sciences, Sangamo Biosciences, Novo Nordisk, Pfizer,
Contracted Research: Baxalta/Shire, Biogen Idec, CSL Behring, Daiichi Sankyo, Kedrion, Novo Nordisk, Octapharma, OPKO Biologics, Prometic Life Sciences.

Note: All honoraria and income are paid to the Indiana Hemophilia & Thrombosis Center. Dr Shapiro has no financial interest in any of the above listed companies.
Robert Sidonio, Jr, MD

Consulting Fees: Shire, Bioverativ, CSL Behring, Emergent Solutions, Grifols, LFB, Novo Nordisk, Pfizer, Grifols, Genentech
Contracted Research: Bioverativ, Bayer and Shire

Michelle L. Witkop DNP, FNP-BC

Consulting Fees: Apetvo, Baxalta/Shire, Biogen Idec, Pfizer, Inc., NHF, Novo Nordisk
Fees for Non-CME/CE Services: Aptevo, Novo Nordisk, Pfizer, Inc.
Contracted Research: Pfizer, Inc., Biogen Idec, Novo Nordisk

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers: Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN; Jan Schultz, RN, MSN, CHCP

Have no real or apparent conflicts of interest to report.

Educational Concepts in Medicine: Patrick J. Crowley, MBA, Partner/CEO; Jodi Andrews, BS, Partner/COO, Jo-Ann Angelucci, BA, Program Director; Helen Morfit, BS, Program Director; Larry Rosenberg, PhD, Medical Writer Have no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM and Educational Concepts in Medicine do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Support
This activity is supported by an educational grant from Novo Nordisk.